4b1895 | Toa Biopharma Co., Ltd., Japan, represented by Toa Biopharma Co., Ltd., Europe Representative Office | Bacillus subtilis FERM BP-07462,Enterococcus lactis FERM BP-10867 andClostridium butyricum FERM BP-10866 | Additive compositionPreparation of Bacillus subtilis FERM BP-07462,Enterococcus lactis FERM BP-10867 andClostridium butyricum FERM BP-10866 containing a minimum of 12 × 108 CFU/g additive(1:10:1 ratio)Solid formCharacterisation of the active substanceViable spores of Bacillus subtilis FERM BP-07462,Enterococcus lactis FERM BP-10867 andClostridium butyricum FERM BP-10866Analytical methodIdentification: DNA sequencing methods or Pulsed Field Gel Electrophoresis (PFGE) – CEN/TS 17697.Enumeration in the feed additive, premixtures, compound feed and water of:Bacillus subtilis FERM BP-07462: Spread plate method on tryptone soya agar (EN 15784)Enterococcus lactis FERM BP-10867: Spread plate method using bile esculin azide agar (EN 15788)Clostridium butyricum FERM BP-10866: Pour plate method using iron sulfite agar (ISO 15213) | All poultry species for fatteningAll poultry species reared for layingAll poultry species reared for breeding | - | 2,4 × 108 | - | 1,2 × 108 | - | - 1.In the directions for use of the additive and premixtures, the storage conditions and stability to heat treatment shall be indicated.
- 2.The additive may be used via water for drinking.
- 3.The additive may be used simultaneously with the following coccidiostats, in accordance with their respective conditions of authorisation as feed additives: diclazuril, decoquinate and halofuginone.
- 4.For users of the additive and premixtures, feed business operators shall establish operational procedures and organisational measures to address potential risks resulting from their use. Where those risks cannot be eliminated by such procedures and measures, the additive and premixtures shall be used with personal breathing and skin protective equipment.
| 24 September 2034 |